BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 37053013)

  • 1. Multiomics of Bohring-Opitz syndrome truncating ASXL1 mutations identify canonical and noncanonical Wnt signaling dysregulation.
    Lin I; Wei A; Awamleh Z; Singh M; Ning A; Herrera A; ; Russell BE; Weksberg R; Arboleda VA
    JCI Insight; 2023 May; 8(10):. PubMed ID: 37053013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical management of patients with ASXL1 mutations and Bohring-Opitz syndrome, emphasizing the need for Wilms tumor surveillance.
    Russell B; Johnston JJ; Biesecker LG; Kramer N; Pickart A; Rhead W; Tan WH; Brownstein CA; Kate Clarkson L; Dobson A; Rosenberg AZ; Vergano SA; Helm BM; Harrison RE; Graham JM
    Am J Med Genet A; 2015 Sep; 167A(9):2122-31. PubMed ID: 25921057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening of CD96 and ASXL1 in 11 patients with Opitz C or Bohring-Opitz syndromes.
    Urreizti R; Roca-Ayats N; Trepat J; Garcia-Garcia F; Aleman A; Orteschi D; Marangi G; Neri G; Opitz JM; Dopazo J; Cormand B; Vilageliu L; Balcells S; Grinberg D
    Am J Med Genet A; 2016 Jan; 170A(1):24-31. PubMed ID: 26768331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel truncating mutations in ASXL1 identified in two boys with Bohring-Opitz syndrome.
    Zhao J; Hou Y; Fang F; Ding C; Yang X; Li J; Cui D; Cao Z; Zhang H
    Eur J Med Genet; 2021 Mar; 64(3):104155. PubMed ID: 33529703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. De novo nonsense mutations in ASXL1 cause Bohring-Opitz syndrome.
    Hoischen A; van Bon BW; Rodríguez-Santiago B; Gilissen C; Vissers LE; de Vries P; Janssen I; van Lier B; Hastings R; Smithson SF; Newbury-Ecob R; Kjaergaard S; Goodship J; McGowan R; Bartholdi D; Rauch A; Peippo M; Cobben JM; Wieczorek D; Gillessen-Kaesbach G; Veltman JA; Brunner HG; de Vries BB
    Nat Genet; 2011 Jun; 43(8):729-31. PubMed ID: 21706002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical findings in 39 individuals with Bohring-Opitz syndrome from a global patient-driven registry with implications for tumor surveillance and recurrence risk.
    Russell BE; Kianmahd RR; Munster C; Yu A; Ahad L; Tan WH
    Am J Med Genet A; 2023 Apr; 191(4):1050-1058. PubMed ID: 36751885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A
    Zhao W; Hu X; Liu Y; Wang X; Chen Y; Wang Y; Zhou H
    Front Pediatr; 2021; 9():678615. PubMed ID: 34527642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathological ASXL1 Mutations and Protein Variants Impair Neural Crest Development.
    Matheus F; Rusha E; Rehimi R; Molitor L; Pertek A; Modic M; Feederle R; Flatley A; Kremmer E; Geerlof A; Rishko V; Rada-Iglesias A; Drukker M
    Stem Cell Reports; 2019 May; 12(5):861-868. PubMed ID: 31006630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bohring-Opitz syndrome (BOS) with a new ASXL1 pathogenic variant: Review of the most prevalent molecular and phenotypic features of the syndrome.
    Dangiolo SB; Wilson A; Jobanputra V; Anyane-Yeboa K
    Am J Med Genet A; 2015 Dec; 167A(12):3161-6. PubMed ID: 26364555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two novel patients with Bohring-Opitz syndrome caused by de novo ASXL1 mutations.
    Magini P; Della Monica M; Uzielli ML; Mongelli P; Scarselli G; Gambineri E; Scarano G; Seri M
    Am J Med Genet A; 2012 Apr; 158A(4):917-21. PubMed ID: 22419483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA methylation signature associated with Bohring-Opitz syndrome: a new tool for functional classification of variants in ASXL genes.
    Awamleh Z; Chater-Diehl E; Choufani S; Wei E; Kianmahd RR; Yu A; Chad L; Costain G; Tan WH; Scherer SW; Arboleda VA; Russell BE; Weksberg R
    Eur J Hum Genet; 2022 Jun; 30(6):695-702. PubMed ID: 35361921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bohring-Opitz syndrome caused by an ASXL1 mutation inherited from a germline mosaic mother.
    Bedoukian E; Copenheaver D; Bale S; Deardorff M
    Am J Med Genet A; 2018 May; 176(5):1249-1252. PubMed ID: 29681100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathogenic ASXL1 somatic variants in reference databases complicate germline variant interpretation for Bohring-Opitz Syndrome.
    Carlston CM; O'Donnell-Luria AH; Underhill HR; Cummings BB; Weisburd B; Minikel EV; Birnbaum DP; ; Tvrdik T; MacArthur DG; Mao R
    Hum Mutat; 2017 May; 38(5):517-523. PubMed ID: 28229513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A
    Efthymiou S; Salpietro V; Pironti E; Bonsignore M; Ferrazzoli V; Rosa GD; Houlden H
    J Genet; 2019 Dec; 98():. PubMed ID: 31819025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of Asxl1 Alters Self-Renewal and Cell Fate of Bone Marrow Stromal Cell, Leading to Bohring-Opitz-like Syndrome in Mice.
    Zhang P; Xing C; Rhodes SD; He Y; Deng K; Li Z; He F; Zhu C; Nguyen L; Zhou Y; Chen S; Mohammad KS; Guise TA; Abdel-Wahab O; Xu M; Wang QF; Yang FC
    Stem Cell Reports; 2016 Jun; 6(6):914-925. PubMed ID: 27237378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extending the phenotypic spectrum of Bohring-Opitz syndrome: Mild case confirmed by functional studies.
    Leon E; Diaz J; Castilla-Vallmanya L; Grinberg D; Balcells S; Urreizti R
    Am J Med Genet A; 2020 Jan; 182(1):201-204. PubMed ID: 31692235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncogenic gene expression and epigenetic remodeling of cis-regulatory elements in ASXL1-mutant chronic myelomonocytic leukemia.
    Binder M; Carr RM; Lasho TL; Finke CM; Mangaonkar AA; Pin CL; Berger KR; Mazzone A; Potluri S; Ordog T; Robertson KD; Marks DL; Fernandez-Zapico ME; Gaspar-Maia A; Patnaik MM
    Nat Commun; 2022 Mar; 13(1):1434. PubMed ID: 35301312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo.
    Abdel-Wahab O; Gao J; Adli M; Dey A; Trimarchi T; Chung YR; Kuscu C; Hricik T; Ndiaye-Lobry D; Lafave LM; Koche R; Shih AH; Guryanova OA; Kim E; Li S; Pandey S; Shin JY; Telis L; Liu J; Bhatt PK; Monette S; Zhao X; Mason CE; Park CY; Bernstein BE; Aifantis I; Levine RL
    J Exp Med; 2013 Nov; 210(12):2641-59. PubMed ID: 24218140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expanding the clinical spectrum of recessive truncating mutations of
    Bruel AL; Bigoni S; Kennedy J; Whiteford M; Buxton C; Parmeggiani G; Wherlock M; Woodward G; Greenslade M; Williams M; St-Onge J; Ferlini A; Garani G; Ballardini E; van Bon BW; Acuna-Hidalgo R; Bohring A; Deleuze JF; Boland A; Meyer V; Olaso R; Ginglinger E; Study D; Rivière JB; Brunner HG; Hoischen A; Newbury-Ecob R; Faivre L; Thauvin-Robinet C; Thevenon J
    J Med Genet; 2017 Dec; 54(12):830-835. PubMed ID: 29074562
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.